84 results on '"Drummond, Michael"'
Search Results
2. Colonoscopy vs the Fecal Immunochemical Test: Which is Best?
3. Estimation of Societal Values of Health States Preferences at the National Level for Low- and Middle-Income Countries
4. Transparency, openness, and reproducible research practices are frequently underused in health economic evaluations
5. Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration
6. GRADE guidance 23: considering cost-effectiveness evidence in moving from evidence to health-related recommendations
7. Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report
8. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
9. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force
10. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
11. Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective
12. A Value Framework for the Assessment of Diagnostic Technologies: A Proposal Based on a Targeted Systematic Review and a Multistakeholder Deliberative Process in Latin America
13. Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis
14. Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy
15. Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America
16. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA
17. Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]
18. A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]
19. Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report [4]
20. ISPOR Code of Ethics 2017 (4th Edition)
21. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward
22. Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?
23. Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation
24. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
25. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
26. Assessing the Added Value of Health Technologies: Reconciling Different Perspectives
27. The Use and Performance of Productivity Scales to Evaluate Presenteeism in Mood Disorders
28. Quality-Adjusted Life Years, Quality-Adjusted Life-Year-Like Measures, or Neither? The Debate Continues
29. Early Dialogue Between the Developers of New Technologies and Pricing and Reimbursement Agencies: A Pilot Study
30. What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?
31. Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
32. Economic Evaluation for Devices and Drugs—Same or Different?
33. Can NICE Be Nicer? In a World of Budget Constraints There Are No Easy Solutions
34. Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom
35. Toward a Consensus on the QALY
36. Retaining, and Enhancing, the QALY
37. Moving the QALY Forward: Rationale for Change
38. Continuous Oxygen Use in Nonhypoxemic Emphysema Patients Identifies a High-Risk Subset of Patients: Retrospective Analysis of the National Emphysema Treatment Trial
39. Economic Evaluation of Adolescent Addiction Programs: Methodologic Challenges and Recommendations
40. Data Privacy and Health: How Do We Achieve the Right Balance?
41. Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome: An Analysis of the TENOR Study
42. The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years: An International Model
43. Twenty-Five Years of Health Economics and Outcomes Research: An Exploration of Value in Health
44. Collection of Health-Economic Data Alongside Clinical Trials: Is There a Future for Piggyback Evaluations?
45. Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability
46. An Economic Evaluation of Sequential IV/po Moxifloxacin Therapy Compared to IV/po Co-amoxiclav With or Without Clarithromycin in the Treatment of Community-Acquired Pneumonia
47. A Cost-Effectiveness Analysis of Eletriptan 40 and 80 mg versus Sumatriptan 50 and 100 mg in the Acute Treatment of Migraine
48. Do Health-Care Decision Makers Find Economic Evaluations Useful? The Findings of Focus Group Research in UK Health Authorities
49. sm“FISH”ing for Hedgehog
50. Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.